The RNA control kits, manufactured under cGMP, will enable Affymetrix to deliver a complete solution to its molecular diagnostic partners. The products will be configured for use with the GeneChip System 3000Dx v.2. This is the available diagnostic microarray platform that has earned 510(k) clearance from the FDA and the CE mark from the European Union.

Matt Winkler, chief executive officer and chief scientific officer of Asuragen, said: “Affymetrix offers a continuous path to discover, develop, and commercialize biomarker signature assays. Affymetrix is partnering with the world’s leading diagnostic companies through the Powered by Affymetrix (PbA) Program to bring to market new diagnostic tests that employ the latest genomic discoveries.

“There are currently more than 20 different molecular assay tests based on the Affymetrix platform under development by Affymetrix and its 11 PbA Partners. The resulting microarray-based tests will enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from complex diseases like cancer.”

Asuragen is the partner for contract development and GMP manufacturing of RNA- and DNA-based standards and controls including plasmid DNA, Armored RNA, and capped and uncapped IVT RNA. Asuragen’s commitment to quality and innovation has helped to establish its highly stable, nuclease-resistant Armored RNA technology as the preferred positive control format for infectious disease molecular diagnostic tests.